Quince Therapeutics, Inc.
QNCX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $81 | $39 | $21 | $375 |
| - Cash | $6 | $21 | $45 | $70 |
| + Debt | $15 | $14 | $0 | $1 |
| Enterprise Value | $89 | $32 | -$23 | $306 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$36 | -$27 | -$51 | -$90 |
| % Margin | – | – | – | – |
| Net Income | -$57 | -$31 | -$52 | -$90 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.31 | -0.84 | -1.54 | -3.03 |
| % Growth | -56% | 45.5% | 49.2% | – |
| Operating Cash Flow | -$32 | -$18 | -$44 | -$63 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$32 | -$18 | -$44 | -$63 |